IL32 and lung carcinoma: An intriguing aspect is the frequent expression of IL32's known receptor, arginylglycylaspartic acid (RGD) binding integrin (such as β5‐integrin),[21] in lung cancer cells.[22] Furthermore, there is an active area of research investigating whether IL32 influences cancer cell sensitivity to TKIs and whether PCs are the main source of this cytokine for this specific regulatory purpose.